Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 268

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists

Bergstrom, Laurie, Yocum, David E., Ampel, Neil M., Villanueva, Isidro, Lisse, Jeffrey, Gluck, Oscar, Tesser, John, Posever, James, Miller, Margaret, Araujo, Julio, Kageyama, Dana M., Berry, Martin, Karl, Linda, Yung, Christianne M.·2004·Arthritis & Rheumatism

Abstract

Objective: To describe a group of patients who were treated with tumor necrosis factor α (TNFα) antagonists and who developed coccidioidomycosis, and to test the hypothesis that patients with inflammatory arthritis receiving TNFα antagonist therapy are at higher risk for developing symptomatic coccidioidomycosis. Methods: Cases of coccidioidomycosis were identified and reviewed from among patients receiving TNFα antagonist therapy from May 1998 through February 2003 in 5 practices within the areas endemic for coccidioidomycosis (Arizona, California, and Nevada). In addition, the relative risk of developing symptomatic coccidioidomycosis was calculated in patients with inflammatory arthritis who were receiving treatment with infliximab, in comparison with patients with inflammatory arthritis who were not receiving infliximab, from January 2000 to February 2003 in a single medical center. Results: Thirteen cases of documented coccidioidomycosis were associated with TNFα antagonist therapy. Twelve cases were associated with the use of infliximab and 1 case with etanercept. Among the cohort of patients from a single medical center, 7 of the 247 patients receiving infliximab and 4 of the 738 patients receiving other therapies developed symptomatic coccidioidomycosis (relative risk 5.23, 95% confidence interval 1.54–17.71; P < 0.01). Conclusion: Patients with inflammatory arthritis who are undergoing treatment with infliximab appear to be at higher risk for developing symptomatic coccidioidomycosis as compared with those not receiving infliximab.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.20454

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 268

Metadata

Authors
Bergstrom, L., Yocum, D. E., Ampel, N. M., Villanueva, I., Lisse, J., Gluck, O., Tesser, J., Posever, J., Miller, M., Araujo, J., Kageyama, D. M., Berry, M., Karl, L., & Yung, C. M.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2004-06
Volume
50
Issue
6
Pages
1959-1966
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2052964479
Cited by
268
References
16
FWCI
11.93
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists. https://app.cochat.ai/papers/10.1002/art.20454
The paper
Bergstrom, L., Yocum, D. E., Ampel, N. M., Villanueva, I., Lisse, J., Gluck, O., Tesser, J., Posever, J., Miller, M., Araujo, J., Kageyama, D. M., Berry, M., Karl, L., & Yung, C. M. (2004). Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists. Arthritis & Rheumatism. https://doi.org/10.1002/art.20454

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.